PRINCETON, N.J., June 2, 2025 -- PDS Biotechnology Corporation (Nasdaq: PDSB), a late-stage immunotherapy company, announced the publication of three Versamune® HPV abstracts on the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting website. These abstracts detail studies involving PDS Biotech's Versamune® HPV (PDS0101) and were presented during the Head and Neck Cancer Poster Session in Chicago, Illinois. The company's ongoing research is focused on HPV16-positive head and neck squamous cell carcinoma (HNSCC), a rapidly growing and significant medical concern. The VERSATILE-003 Phase 3 clinical trial is currently the only registrational trial exclusively targeting first-line recurrent/metastatic HPV16-positive HNSCC. This trial aims to evaluate the effectiveness of an HPV16-targeted T cell immunotherapy. The median overall survival data for this patient population remains durable at 30.0 months, following an additional 4.5 months of follow-up beyond the initial abstract.